In breast cancer, expression profiling has helped in the identification of ER (estrogen-receptor)-positive and ER-negative cancers as fundamentally distinct diseases at the molecular level [6, 7] as well as shown that prognosis of patients with ER-positive disease is largely determined by the expression of proliferation-related genes [8]. This evidence concerns the gene ESR1 and breast cancer.